In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa

@article{Morinaka2017InVA,
  title={In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa},
  author={Akihiro Morinaka and Yuko Tsutsumi and Keiko Yamada and Yoshihiro Takayama and Shiro Sakakibara and Toshihiko Takata and Takao Abe and Takeshi Furuuchi and Seiichi Inamura and Yoshiaki Sakamaki and Nakako Tsujii and Takashi Ida},
  journal={The Journal of Antibiotics},
  year={2017},
  volume={70},
  pages={246-250}
}
Pseudomonas aeruginosa is a common cause for healthcare-associated infections, which have been historically treated by antipseudomonal β-lactam agents in the clinical setting. However, P. aeruginosa has evolved to overcome these β-lactam agents via multiple endogenous resistance mechanisms, including derepression of the chromosomal cephalosporinase (AmpC). In this article, we investigated the effective concentration of OP0595 for combination with piperacillin, cefepime or meropenem in in vitro… CONTINUE READING